Background: Cancer-related cognitive impairment (CRCI) is among the most frequently reported adverse events during and following cancer treatment. Between 17% to 75% of chemotherapy-treated cancer patients evidence long-term cognitive deficits as many as 20 years after treatment. The variability in prevalence and the mechanisms of persistent CRCI are not well...